CERE Stock Overview
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cerevel Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.90 |
| 52 Week High | US$43.59 |
| 52 Week Low | US$19.59 |
| Beta | 1.49 |
| 1 Month Change | -1.18% |
| 3 Month Change | -0.48% |
| 1 Year Change | 49.27% |
| 3 Year Change | 170.50% |
| 5 Year Change | n/a |
| Change since IPO | 252.10% |
Recent News & Updates
Recent updates
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02
Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease
Oct 30Shareholder Returns
| CERE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | 1.5% | 1.2% |
| 1Y | 49.3% | 1.1% | 24.7% |
Return vs Industry: CERE exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CERE exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| CERE volatility | |
|---|---|
| CERE Average Weekly Movement | 1.5% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CERE has not had significant price volatility in the past 3 months.
Volatility Over Time: CERE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 334 | Ron Renaud | www.cerevel.com |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder.
Cerevel Therapeutics Holdings, Inc. Fundamentals Summary
| CERE fundamental statistics | |
|---|---|
| Market cap | US$7.62b |
| Earnings (TTM) | -US$432.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.6x
P/E RatioIs CERE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$432.84m |
| Earnings | -US$432.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 66.7% |
How did CERE perform over the long term?
See historical performance and comparison